Inexpensive Drug May Counteract Leukemia Treatment-Resistance
A real estate investment and management professional with a career that spans nearly 35 years, Gene Berman most recently as a group manager/executive vice president and director of training and development with Marcus & Millichap in Fort Lauderdale, Florida. Adding to his diverse work in the real estate sector, Gene Berman counts leukemia research among his primary interests.
A new study by Karolinska Institutet and SciLifeLab has found a promising new way to overcome treatment-resistance in acute myeloid leukemia (AML) patients. Published in the January 2020 issue of the medical journal EMBO Molecular Medicine, this study examined the blood cells of both mice and human beings.
Although physicians have long used cytarabine to treat AML, many patients are resistant to this cytotoxic drug. After testing the impact of over 33,000 different substances on leukemia cells treated with cytarabine, the Karolinska Institutet/SciLifeLab study determined that the cheap, FDA-approved and readily-available cancer drug hydroxyurea proved highly effective in overcoming cytarabine resistance.
A new study by Karolinska Institutet and SciLifeLab has found a promising new way to overcome treatment-resistance in acute myeloid leukemia (AML) patients. Published in the January 2020 issue of the medical journal EMBO Molecular Medicine, this study examined the blood cells of both mice and human beings.
Although physicians have long used cytarabine to treat AML, many patients are resistant to this cytotoxic drug. After testing the impact of over 33,000 different substances on leukemia cells treated with cytarabine, the Karolinska Institutet/SciLifeLab study determined that the cheap, FDA-approved and readily-available cancer drug hydroxyurea proved highly effective in overcoming cytarabine resistance.
